Omadacycline: A Newly Approved Antibacterial from the Class of Tetracyclines

Omadacycline (Nuzyra®) is a new aminomethylcycline, approved by the U. S. Food and Drug Administration in 2018, as a tetracycline antibacterial. It can be used in community-acquired pneumonia and in acute bacterial skin and skin-structure infections. It was developed and is commercialized by Paratek...

Descripción completa

Detalles Bibliográficos
Autores principales: Durães, Fernando, Sousa, Emília
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6630996/
https://www.ncbi.nlm.nih.gov/pubmed/31010063
http://dx.doi.org/10.3390/ph12020063
_version_ 1783435426887892992
author Durães, Fernando
Sousa, Emília
author_facet Durães, Fernando
Sousa, Emília
author_sort Durães, Fernando
collection PubMed
description Omadacycline (Nuzyra®) is a new aminomethylcycline, approved by the U. S. Food and Drug Administration in 2018, as a tetracycline antibacterial. It can be used in community-acquired pneumonia and in acute bacterial skin and skin-structure infections. It was developed and is commercialized by Paratek Pharmaceuticals. It is a semisynthetic compound, derived from minocycline, capable of evading widely distributed efflux and target protection antibacterial resistance mechanisms and has demonstrated activity in a broad spectrum of bacteria.
format Online
Article
Text
id pubmed-6630996
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-66309962019-08-19 Omadacycline: A Newly Approved Antibacterial from the Class of Tetracyclines Durães, Fernando Sousa, Emília Pharmaceuticals (Basel) Brief Report Omadacycline (Nuzyra®) is a new aminomethylcycline, approved by the U. S. Food and Drug Administration in 2018, as a tetracycline antibacterial. It can be used in community-acquired pneumonia and in acute bacterial skin and skin-structure infections. It was developed and is commercialized by Paratek Pharmaceuticals. It is a semisynthetic compound, derived from minocycline, capable of evading widely distributed efflux and target protection antibacterial resistance mechanisms and has demonstrated activity in a broad spectrum of bacteria. MDPI 2019-04-21 /pmc/articles/PMC6630996/ /pubmed/31010063 http://dx.doi.org/10.3390/ph12020063 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Brief Report
Durães, Fernando
Sousa, Emília
Omadacycline: A Newly Approved Antibacterial from the Class of Tetracyclines
title Omadacycline: A Newly Approved Antibacterial from the Class of Tetracyclines
title_full Omadacycline: A Newly Approved Antibacterial from the Class of Tetracyclines
title_fullStr Omadacycline: A Newly Approved Antibacterial from the Class of Tetracyclines
title_full_unstemmed Omadacycline: A Newly Approved Antibacterial from the Class of Tetracyclines
title_short Omadacycline: A Newly Approved Antibacterial from the Class of Tetracyclines
title_sort omadacycline: a newly approved antibacterial from the class of tetracyclines
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6630996/
https://www.ncbi.nlm.nih.gov/pubmed/31010063
http://dx.doi.org/10.3390/ph12020063
work_keys_str_mv AT duraesfernando omadacyclineanewlyapprovedantibacterialfromtheclassoftetracyclines
AT sousaemilia omadacyclineanewlyapprovedantibacterialfromtheclassoftetracyclines

Ejemplares similares